Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 113 of 5804
-
Electric field therapy extends life in advanced lung cancer trial
Disease control CompletedThe study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment. The…
Phase: PHASE3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New stem cell approach could fix immune systems in kids
Disease control OngoingThis is a Phase II trial to determine the ability of a reduced intensity conditioning regimen to allow successful engraftment with alpha/beta T and CD19+ depleted peripheral stem cell grafts from unrelated or partially matched related donors. There are two conditioning regimens d…
Phase: PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo shows promise for advanced prostate cancer
Disease control CompletedThe purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Promising combo therapy aims to beat B-ALL without transplant
Disease control Recruiting nowThis phase II trial studies how well blinatumomab, inotuzumab ozogamicin, and combination chemotherapy work as frontline therapy in treating patients with B acute lymphoblastic leukemia. Immunotherapy with monoclonal antibodies, such as blinatumomab, may induce changes in the bod…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Genetic roadmap guides new hope for tough leukemia
Disease control Recruiting nowThis screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, …
Phase: PHASE1, PHASE2 • Sponsor: Beat AML, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
HIV patients may ditch daily pills for monthly shots
Disease control OngoingThe First Long-Acting Injectable Regimen (FLAIR) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult participants whose virus is virologically suppressed on an integrase inhibitor single tablet regimen (INI STR) will remain suppress…
Phase: PHASE3 • Sponsor: ViiV Healthcare • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug cocktails show promise in slowing advanced kidney cancer
Disease control OngoingThe primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review \[IIR\] using Response Ev…
Phase: PHASE3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Womb transplants offer hope for women unable to carry a pregnancy
Disease control ENROLLING_BY_INVITATIONTransplantation of an uterus
Phase: NA • Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New drugs aim to keep boys with duchenne walking longer
Disease control CompletedThe main objective of this study is to evaluate the efficacy of SRP-4045 (casimersen) and SRP-4053 (golodirsen) compared to placebo in participants with DMD with out-of-frame deletion mutations amenable to skipping exon 45 and exon 53, respectively.
Phase: PHASE3 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
French study aims to perfect leukemia treatment for kids
Disease control OngoingA still major question in the field of acute lymphoblastic leukemia (ALL) in children - an extremely heterogeneous disease though curable in 80-90% of children and 70-80% of the adolescents - is the optimal use of L-asparaginase (ASNase). It is known that administering ASNase res…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 18:21 UTC
-
Immunotherapy combo boosts survival in advanced kidney cancer
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for participants with advanced/metastatic renal cell carcinoma (mRCC). The primary hypotheses of this s…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for rare blood disorder: Half-Matched transplants show promise
Disease control Recruiting nowSevere aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of surviva…
Phase: PHASE2 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug alectinib outperforms standard therapy in asian lung cancer patients
Disease control CompletedThis randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of alectinib versus crizotinib and to evaluate the pharmacokinetics of alectinib in asian participants with treatment-naive ALK-positive advanced NSCLC. Participants will be randomized…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for leukemia patients who Can't handle strong chemo
Disease control CompletedThis was a clinical study for adult participants who were recently diagnosed with acute myeloid leukemia or AML. AML is a type of cancer. It is when bone marrow makes white blood cells that are not normal. These are called leukemia cells. Some participants with AML have a mutatio…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Tailored combo therapy boosts leukemia fight in adults
Disease control CompletedA phase IV study with the primary goal to optimize therapy of adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma (LBL) by dose and time intensive, pediatric based chemotherapy, risk adapted stem cell transplantation (SCT) and minimal residual disease (MRD)…
Phase: PHASE3 • Sponsor: Goethe University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Immunotherapy after surgery may keep lung cancer at bay
Disease control OngoingThis phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the ca…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy after surgery may keep esophageal cancer at bay
Disease control CompletedThe primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Brain gene therapy trial offers hope for kids with rare movement disorder
Disease control Recruiting nowThe overall objective of this study is to determine the safety and efficacy of AAV2-hAADC delivered to the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) in children with aromatic L-amino acid decarboxylase (AADC) deficiency.
Phase: PHASE1 • Sponsor: Krzysztof Bankiewicz • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Immunotherapy avelumab aims to stop triple negative breast cancer recurrence
Disease control CompletedPhase III randomized trial of the anti-PD-L1 antibody avelumab as adjuvant or post-neoadjuvant treatment for high-risk triple negative breast cancer patients. The overall protocol-defined patient population will include the following two strata of patients: * Stratum A - Patient…
Phase: PHASE3 • Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Immunotherapy combo shows promise in advanced lung cancer trial
Disease control CompletedThe objective of the trial is to demonstrate that the addition of neoadjuvant and adjuvant immunotherapy (with the anti-PD-L1 antibody MEDI4736) to standard neoadjuvant chemotherapy (with cisplatin/docetaxel) in primary resectable stage IIIA(N2) NSCLC is efficacious and feasible.
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC